Table 2.
Baseline characteristics of included studies
| First author (year) | Study design | Participants | Country | Female (%) | Age Median (range) |
Type of the therapy | outcome | Adverse events |
|---|---|---|---|---|---|---|---|---|
| Younes et al. (2019) [12] | RCT | 141 | Multinational | 38 | 65 (54–71) | Combination therapy | CR, ORR | Neutropenia, Anemia, Thrombocytopenia, Rash, HTN |
| Fraser et al. (2020) [13] | RCT | 578 | Multinational | Not specified | Not specified | Combination therapy | CR, ORR | Not specified |
| Hillmen et al. (2023) [14] | RCT | 652 | Multinational | 28.2 | Not specified | Monotherapy | CR, ORR | Neutropenia, Anemia, Thrombocytopenia, Diarrhea, HTN, Hemorrhage, Pneumonia, URTI |
| Huang et al. (2017) [15] | RCT | 160 | China | 29.4 | 66 (21–87) | Monotherapy | CR, ORR | Neutropenia, Anemia, Diarrhea, Thrombocytopenia, Asthenia/Fatigue, Rash, Nausea, URTI |
| Brown et al. (2015) [16] | RCT | 391 | U.S.A | Not specified | 67 | Combination therapy | CR, ORR | Neutropenia, Anemia, Thrombocytopenia, Asthenia/Fatigue, Diarrhea, Nausea, Pneumonia, URTI |
| Göçer et al. (2020) [17] | Cohort | 32 | Turkey | 36.4 | 65 (51–80) | Monotherapy | CR, ORR | Neutropenia, Anemia, Thrombocytopenia, Lymphocytosis, Diarrhea, Hemorrhage, Pneumonia |
| Pula et al. (2020) [18] | Cohort | 171 | Poland | 44.4 | 63 (39–85) | Monotherapy | CR, ORR | Neutropenia, Thrombocytopenia, AF, Diarrhea, Rash, HTN, Nausea, Hemorrhage, Pneumonia, URTI |
| Akhtar et al. (2017) [19] | Cohort | 144 | U.S.A | Not specified | Not specified | Monotherapy | CR, ORR | Not specified |
| Michallet et al. (2019) [20] | Cohort | 56 | France | 36 | 48 (35–64) | Monotherapy | CR, ORR | Not specified |
| Broccoli et al. (2021) [21] | Cohort | 46 | Italy | 32.6 | 62 (33–79) | Monotherapy | CR, ORR, OS | Not specified |
| Bonfiglio et al. (2023) [22] | Cohort | 98 | Multinational | 34.7 | 66 (33–86) | Monotherapy | CR, OS | Not specified |
| Byrd et al. (2015) [23] | Cohort | 132 | U.S.A | 22 | 64 (37–82) | Monotherapy | CR, ORR | Neutropenia, Thrombocytopenia, Lymphocytosis, Asthenia/Fatigue, AF, Diarrhea, HTN, Pneumonia |
| Omi et al. (2022) [24] | Cohort | 323 | Japan | 34.6 | 72 (33–92) | Monotherapy | ORR | Thrombocytopenia, Lymphocytosis, AF, Hemorrhage |
| Hansson et al. (2015) [25] | Cohort | 97 | Sweden | Not specified | 69 | Monotherapy | ORR | Neutropenia, AF, Diarrhea, Hemorrhage |
| Brown et al. (2015) [26] | Cohort | 33 | U.S.A | 16.7 | 62 (41–82) | Monotherapy | ORR | Not specified |
| Wierda et al. (2020) [27] | Cohort | 19 | U.S.A | Not specified | 60 (50–77) | Combination therapy | CR, ORR | Neutropenia, Anemia, AF, Diarrhea, Rash, HTN, Pneumonia |
| Burger et al. (2014) [28] | Case-series | 40 | U.S.A | 35 | 63.2 (35–82) | Combination therapy | CR | Neutropenia, Anemia, Asthenia/Fatigue, AF, Diarrhea, Nausea, URTI |
| Brown et al. (2023) [29] | RCT | 652 | Multinational | 31.5 | 67 (35–90) | Monotherapy | ORR | Neutropenia, Diarrhea, HTN, URTI, Covid-19 |
| Byrd et al. (2020) [30] | Cohort | 132 | Multinational | 25.8 | 66.5 (37–84) | Monotherapy | CR, OS |
Neutropenia HTN, Pneumonia |
| Byrd et al. (2021) [31] | RCT | 533 | Multinational | 26.8 | 66 (28–89) | Monotherapy | ORR | HTN, AF, Infection |
| Munir et al. (2019) [32] | RCT | 391 | Multinational | 32 | 67 (37–90) | Monotherapy | ORR |
Neutropenia HTN, Pneumonia, AF |
Abbreviations: CR complete response; ORR overall response rate; AF atrial fibrillation; HTN hypertension; RCT randomized controlled trial; URTI upper respiratory tract infection; OS overall survival